UEFA Women's Euro 2025 Quarterfinals Kick Off Tomorrow
The knockout rounds are here, and the UEFA Women's Euro 2025 has already made history — with nearly 500,000 fans showing up for the group stage and host nation Switzerland reaching the quarters for the first time. Now, the final eight are set, and there are no easy paths to the trophy.
Here's a quick look at what's ahead, starting tomorrow:
Norway vs Italy (Wed, July 16 – Geneva) Norway cruised through the group with nine points but showed defensive cracks. Italy, back in the quarterfinals for the first time in over a decade, are riding high on belief and hungry to extend their comeback story.
England vs Sweden (Thurs, July 17 – Zurich) The defending champs shook off a shaky start to smash 10 goals in their last two matches. But Sweden — fresh off a 4-1 statement win over Germany — want revenge for their 2022 semifinal exit. This one's a heavyweight clash with serious history.
Spain vs Switzerland (Fri, July 18 – Bern) The hosts are on a dream run, but now face the ultimate test: the world champs. Spain has looked untouchable, with Aitana Bonmatí, Alexia Putellas, and Esther Gonzalez all firing. A sold-out crowd in Bern will be hoping for a miracle.
France vs Germany (Sat, July 19 – Basel) France look like true contenders after dominating the group of death. Germany, meanwhile, are wobbling after a heavy loss to Sweden. Can Les Bleues avenge their 2022 heartbreak and continue their surge?
Four days, four massive fixtures — and starting tomorrow, only four teams will keep their Euro dreams alive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
New test could revolutionise aftercare for thousands of breast cancer patients
Scientists have developed a new test for certain breast cancer patients which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. This is your breast check reminder! Learn the signs and symptoms of breast — Breast Cancer Now (@BreastCancerNow) May 6, 2025 They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
Yahoo
24 minutes ago
- Yahoo
What does LeBron's 'frustration' mean for his Lakers future?
Yahoo Sports fantasy analyst Dan Titus and senior NBA writer Dan Devine discuss Lebron James's reported "frustrations" with the Los Angeles Lakers and what it means for his immediate future with the franchise. Hear the full conversation on 'Good Word with Goodwill' and subscribe on Apple Podcasts, Spotify, YouTube or wherever you listen. View more Video Transcript Unsurprisingly, we saw LeBron make a couple of appearances at Summer League. A report came out from Anthony Irwin, a senior insider at the Lakers, saying that LeBron has become increasingly frustrated. And unhappy with the direction of the team since the Russell Westbrook trade. Is this just noise? What, what are your take on it? Yeah, well, first off, you forgot the main reason he was at Summer League. His son was playing, right? Oh you guys are watching, you gotta watch Bronnie of course last year too, exactly right. Um, and listen, Bronny has given him reason to be excited about watching him play this summer. That's good. It is funny that when you zoom out from all of it, the headline is more like, report, man who opted into contract will stay with team that is paying him. You were absolutely right to point to the notion that it is difficult to trade a $52 million contract. If LeBron James wanted to be anywhere else, he could have opted out. LeBron James isn't gonna go someplace else and sign for, you know, the biannual exception. LeBron James is going to get the, the top possible dollar. The questions moving forward are all about what does this mean like on the court next year? What does this mean when we get to next summer and we revisit this whole question about where does LeBron want to be for the balance of his career? Is he, does he decide that he's done? Does he decide that he wants to play 23 more years? He's gonna stay there to make as much money as he can possibly make right now, because he opted in and said that's what he wanted to do, doesn't seem like a super shock. And then the rest of it is kind of all noise. Yeah, now that the Lakers have new ownership, I'm curious to see where Rob Polinka's place in this standing is. Like, maybe he's bulletproof for a while because he acquired he traded for Luca. Like he got off of that, right? Yeah, yeah, I'm curious to see where this goes. I don't, I don't think this is gonna end up being a midseason trade or anything like that. I think LeBron's gonna play out the final year, and then we'll see what's next. Maybe it's retirement, maybe it's going somewhere else. Close
Yahoo
24 minutes ago
- Yahoo
RSV jab in pregnancy can ‘significantly' cut baby's infection risk, study finds
Vaccinating pregnant women against a virus that causes coughs and colds can 'significantly' reduce the risk their babies will be hospitalised with a serious lung infection, scientists have found. A team of researchers co-led by the University of Edinburgh said giving pregnant women the respiratory syncytial virus (RSV) vaccine led to a 72% reduction in babies being hospitalised with the virus. RSV can lead to a severe lung infection called bronchiolitis, which is dangerous in babies and can result in them being admitted to intensive care. It is the main infectious cause of hospitalisation for babies in the UK and globally. The study saw researchers examine 537 babies across England and Scotland who were admitted to hospital with severe respiratory disease in the winter of 2024-25. A total of 391 of the babies tested positive for RSV. The team found mothers of babies who did not have RSV were twice as likely to have received the vaccine before giving birth than the mothers of RSV-positive babies (41% as opposed to 19%). They also found receiving the vaccine more than two weeks before giving birth increased the level of protection, with a 72% reduction in hospital admissions in this group compared with 58% for babies whose mothers were vaccinated at any time prior to delivery. The RSV vaccine was introduced across the UK in the late summer of 2024. The scientists said it works by causing the mother to produce antibodies – proteins which help prevent the virus causing severe infection – which are then passed to the fetus, providing protection from severe RSV for the first six months of their child's life. They recommend women get vaccinated as soon as possible from 28 weeks of pregnancy to provide the best protection, as this allows more time for the mother to generate and pass on protective antibodies to the baby, but the jab can be given up to birth. They also said previous research shows only half of expectant mothers in England and Scotland are currently receiving the RSV vaccine, despite its high success at preventing serious illness. Study lead Dr Thomas Williams, from the University of Edinburgh's Institute for Regeneration and Repair, said: 'With the availability of an effective RSV vaccine shown to significantly reduce the risk of hospitalisation in young infants in the UK, there is an excellent opportunity for pregnant women to get vaccinated and protect themselves and their infants from RSV bronchiolitis this coming winter.' Professor Damian Roland, from the Leicester Hospitals and University and a consultant in paediatric emergency medicine, said: 'Our work highlights the value of vaccination and in keeping with the treatment to prevention principle of the NHS 10 Year plan, we would ask all health care systems to consider how they will optimise the rollout of RSV vaccination for mothers.' The research team was led by the universities of Edinburgh and Leicester, and was funded by the Innovative Medicines Initiative, Respiratory Syncytial Virus Consortium in Europe, the Wellcome Trust, and National Institute for Health and Care Research at Imperial College London. The study is published in the journal The Lancet Child and Adolescent Health.
